`Filed: February 14, 2017
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`____________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`___________________
`
`NEPTUNE GENERICS, LLC,
`APOTEX INC., APOTEX CORP., TEVA PHARMACEUTICALS,
`FRESENIUS KABI USA, LLC, and
`WOCKHARDT BIO AG,
`
`PETITIONERS,
`
`V.
`
`ELI LILLY & COMPANY,
`
`PATENT OWNER.
`
`
`
`___________________
`
`Case IPR2016-002371
`Patent 7,772,209
`___________________
`
`
`
`PETITIONER’S REQUEST FOR ORAL ARGUMENT
`
`
`1 Cases IPR2016-01190, IPR2016-01335 and IPR2016-01341 have been joined
`with the instant proceeding.
`
`
`
`Pursuant to 37 C.F.R. § 42.70(a), and the Scheduling Order entered on June
`
`17, 2016, IPR2016-00237 Paper 15 at 3; IPR2016-00240 Paper 15 at 3, Petitioner
`
`Neptune Generics, LLC (“Neptune”) respectfully requests the oral argument as
`
`currently scheduled for March 7, 2017.
`
`Without intending to waive any issue not specifically identified, Neptune
`
`identifies below the issues to be argued:
`
`1.
`
`The ground of unpatentability instituted in IPR2016-00237: Claims 1-
`
`22 of U.S. Patent No. 7,772,209 (“the ’209 patent”) as being obvious under 35
`
`U.S.C. § 103 over Niyikiza (Ex. 1008) in view of the ’974 Patent (Ex. 1009) and
`
`further in view of the European Patent Application No. 0 595 005 (“EP 005”) (Ex.
`
`1010), together with the knowledge of the Person of Ordinary Skill in the Art
`
`(“POSA”). Paper 13 at 19.
`
`2.
`
`The ground of unpatentability instituted in IPR2016-00240: Claims 1-
`
`22 of the ’209 patent as being obvious under 35 U.S.C. § 103 on the following
`
`ground Rusthoven (Ex. 1011) in view of EP 005 (Ex. 1010), together with the
`
`knowledge of the POSA. Paper 14 at 19.
`
`3.
`
`Any issues, exhibits, or factual matters raised in Petitioner’s IPR2016-
`
`00237 Petition for an IPR of the ’209 patent. Paper 1.
`
`4.
`
`Any issues, exhibits, or factual matters raised in the Board’s Decision
`
`to institute IPR2016-00237. Paper 13.
`
`
`
`1
`
`
`
`5.
`
`Any issues, exhibits, or factual matters raised in Patent Owner’s
`
`Opposition in IPR2016-00237. Paper 33.
`
`6.
`
`Any issues, exhibits, or factual matters raised in Petitioner’s IPR2016-
`
`00240 Petition for an IPR of the ’209 patent. Paper 1.
`
`7.
`
`Any issues, exhibits, or factual matters raised in the Board’s Decision
`
`to institute IPR2016-00240. Paper 14.
`
`8.
`
`Any issues, exhibits, or factual matters raised in Patent Owner’s
`
`Opposition in IPR2016-00240. Paper 32.
`
`9.
`
`Neptune’s Motion to Exclude in IPR2016-00237 and IPR2016-00240
`
`and any opposition by Patent Owner Eli Lilly and Company (“Lilly”) thereto.
`
`10. Pursuant to the teleconference held January 25, 2017, any issues,
`
`exhibits, or factual matters raised in Lilly’s Sur-Reply, which is due on February
`
`14, 2017.
`
`11. Any issues specified by Lilly in a Request for Oral Argument, but
`
`only to the extent the Board grants Lilly’s Request on those issues.
`
`The ’209 patent is also at issue in IPR2016-00318, which was filed by
`
`Sandoz Inc. (“Sandoz”) and also has an oral argument scheduled for March 7,
`
`2017. IPR2016-00318, Paper 15 at 6. Neptune requests that the arguments for the
`
`Neptune IPRs and Sandoz IPR be scheduled as separate sequential arguments
`
`rather than as a combined oral hearing. Neptune believes the arguments should be
`
`
`
`2
`
`
`
`treated separately because Neptune is not a party to IPR2016-00318. Further, the
`
`Sandoz IPR was instituted on different grounds, specifically, obviousness of claims
`
`1-22 based on: (i) Calvert (Ex. 1007), Niyikiza I (Ex. 1006), Worzalla (Ex. 1013),
`
`European Patent Application No. 0 595 005 (“EP 005”) (Ex. 1033), and the ’974
`
`Patent (Ex. 1005); and (ii) Calvert (Ex. 1007), Niyikiza I (Ex. 1006), Hammond I
`
`(Ex. 1015), EP 005 (Ex. 1033), and the ’974 Patent (Ex. 1005) (IPR2016-00318,
`
`Paper No. 14, at 21). The Sandoz IPR also involves different evidence, including
`
`testimony from three different experts who did not present testimony in the
`
`Neptune IPRs. Thus, given the differences in the parties, grounds, and evidence
`
`between IPR2016-00237 and -00240 on one hand and IPR2016-00318 on the
`
`other, Neptune believes that separate sequential arguments are appropriate.
`
`Because of the technical complexity of the issues in dispute, Neptune,
`
`individually, requests sixty (60) minutes of time to address the issues. Should Lilly
`
`be granted more time for IPR2016-00237 and -00240, Neptune requests an equal
`
`amount of time as Lilly be allocated for Neptune.
`
`Neptune reserves the right for rebuttal. Neptune will inform the Board of its
`
`specific allocation of time for its opening and rebuttal at the beginning of the oral
`
`argument.
`
`
`
`3
`
`
`
`Neptune also requests the ability to use computers at counsel’s table to
`
`display demonstrative exhibits, and respectfully requests that PTAB provide a
`
`projector with VGA and HDMI connections for that purpose.
`
`Respectfully Submitted,
`
`/Sarah E. Spires/
`Sarah E. Spires (Reg. No. 61,501)
`SKIERMONT DERBY LLP
`2200 Ross Ave., Ste. 4800W
`Dallas, Texas 75201
`P: 214-978-6600/F: 214-978-6601
`Lead Counsel for Petitioner
`
`Dr. Parvathi Kota (Reg. No. 65,122)
`Paul J. Skiermont (pro hac vice)
`SKIERMONT DERBY LLP
`2200 Ross Ave., Ste. 4800W
`Dallas, Texas 75201
`P: 214-978-6600/F: 214-978-6621
`
`Mieke K. Malmberg (pro hac vice
`requested)
`SKIERMONT DERBY LLP
`800 Wilshire Boulevard
`Los Angeles, CA 90017
`P: 213-788-4500/F: 213-788-4545
`Back-Up Counsel for Petitioner
`
`
`
`.
`
`
`
`February 14, 2017
`
`
`
`
`
`4
`
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. § 42.6(e), I certify that I caused to be served on the
`
`counsel for Patent Owner a true and correct copy of the foregoing Petitioner’s
`
`Request for Oral Argument, by electronic means on February 14, 2017 at the
`
`following addresses of record:
`
`Dov P. Grossman (Reg. No. 72,525)
`WILLIAMS & CONNOLLY LLP
`725 Twelfth St. NW
`Washington, DC 20005
`Direct Phone: 202-434-5812
`Facsimile: 202-434-5029
`dgrossman@wc.com
`Lead Counsel for Patent Owner
`
`Adam L. Perlman (pro hac vice)
`WILLIAMS & CONNOLLY LLP
`725 Twelfth St. NW
`Washington, DC 20005
`Direct Phone: 202-434-5244
`Facsimile: 202-434-5029
`aperlman@wc.com
`Back-Up Counsel for Patent Owner
`
`John C. Demeter (Reg. No. 30,167)
`ELI LILLY AND COMPANY
`Lilly Corporate Center
`Indianapolis, IN 46285
`Direct Phone: 317-276-3785
`Facsimile: 317-276-3861
`demeter_john_c@lilly.com
`Back-Up Counsel for Patent Owner
`
`
`
`
`
`David M. Krinsky (Reg. No. 72,339)
`WILLIAMS & CONNOLLY LLP
`725 Twelfth St. NW
`Washington, DC 20005
`Direct Phone: 202-434-5338
`Facsimile: 202-480-8302
`dkrinsky@wc.com
`Back-Up Counsel for Patent Owner
`
`James P. Leeds (Reg. No. 35,241)
`ELI LILLY AND COMPANY
`Lilly Corporate Center
`Indianapolis, IN 46285
`Direct Phone: 317-276-1667
`Facsimile: 317-277-6534
`leeds_james@lilly.com
`Back-Up Counsel for Patent Owner
`
`John D. Polivick (Reg. No. 57,926)
`RAKOCZY MOLINO
`MAZZOCHI SIWIK LLP
`6 West Hubbard Street, Suite 500
`Chicago, Illinois 60654
`Tel: 312-527-2157
`Fax: 312-527-4205
`jpolivick@rmmslegal.com
`Lead Counsel for Petitioner Apotex
`
`
`
`
`
`Patrick C. Kilgore (Reg. No. 69,131)
`RAKOCZY MOLINO
`MAZZOCHI SIWIK LLP
`6 West Hubbard Street, Suite 500
`Chicago, Illinois 60654
`Tel: 312-527-2157
`Fax: 312-527-4205
`pkilgore@rmmslegal.com
`Back-Up Counsel for Petitioner Apotex
`
`Mark D. Schuman (Reg. No. 31,197)
`CARLSON, CASPERS, VANDENBURGH,
`LINDQUIST AND SCHUMAN
`225 South Sixth Street, Suite 4200
`Minneapolis, MN 55402
`Tel: 612-436-9600
`Fax: 612-436-9605
`mschuman@carlsoncaspers.com
`Back-Up Counsel for Petitioner Teva
`
`Patrick A. Doody
`(Reg. No. 35,002)
`PILLSBURY WINTHROP SHAW
`PITTMAN LLP
`1650 Tysons Boulevard
`McLean, Virginia 22102
`Tel: 703-770-7538
`Fax: 703-770-7901
`patrick.doody@pillsburylaw.com
`Lead Counsel for Wockhardt Bio AG
`
`Deanne M. Mazzochi (Reg. No. 50,158)
`RAKOCZY MOLINO
`MAZZOCHI SIWIK LLP
`6 West Hubbard Street, Suite 500
`Chicago, Illinois 60654
`Tel: 312-527-2157
`Fax: 312-527-4205
`dmazzochi@rmmslegal.com
`Back-Up Counsel for Petitioner Apotex
`
`Gary J. Speier (Reg. No. 45,458)
`CARLSON, CASPERS, VANDENBURGH,
`LINDQUIST AND SCHUMAN
`225 South Sixth Street, Suite 4200
`Minneapolis, MN 55402
`Tel: 612-436-9600
`Fax: 612-436-9605
`gspeier@carlsoncaspers.com
`Lead Counsel for Petitioner Teva
`
`Cynthia Lambert Hardman
`(Reg. No. 45,458)
`GOODWIN PROCTER LLP
`The New York Times Building
`620 Eighth Avenue
`New York, New York 10018-1405
`Tel: 212-813-8800
`Fax: 212-355-3333
`chardman@goodwinprocter.com
`Back-Up Counsel for Petitioner Teva
`
`
`
`
`
`
`
`
`
`
`
`Respectfully Submitted,
`
`/Sarah E. Spires/
`Sarah E. Spires (Reg. No. 61,501)
`
`Lead Counsel for Petitioner
`
`
`
`Bryan P. Collins
`(Reg. No. 43,560)
`PILLSBURY WINTHROP SHAW
`PITTMAN LLP
`1650 Tysons Boulevard
`McLean, Virginia 22102
`Tel: 703-770-7755
`Fax: 703-770-7901
`bryan.collins@pillsburylaw.com
`Back-Up Counsel for Wockhardt Bio AG
`
`Dated: February 14, 2017
`
`
`
`
`
`
`
`
`
`